試す 金 - 無料
A RELIEF OR ADDED THREAT FOR INDIA?
Bio Spectrum
|May 2020
Researchers across the globe have observed that there may be a unique mutation in the viral strain infecting the Indian population. And may be that is the reason why few countries are suffering large numbers of fatalities as compared to India.
In December 2019, several cases of pneumonia of unknown etiology were reported in Wuhan, Hubei Province, China. The disease which is now called COVID-19 is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was discovered through whole-genome sequencing, polymerase chain reaction (PCR) and culture of bronchoalveolar lavage fluid obtained from affected patients.
Soon after, Chinese researchers revealed that the virus is 96 per cent identical at the whole-genome level to a bat coronavirus. The researchers also announced that the virus uses a same cell entry receptor, angiotensin-converting enzyme 2 (ACE2), for its entry into the host. A spike glycoprotein found on the surface of SARS-CoV-2 is a class I fusion protein which helps the virus in its initial attachment with human ACE2 receptor and its consecutive fusion with the host cells. The attachment is mediated by the S1 subunit of theprotein via its receptor-binding domain.
Simultaneously, researchers across the globe started conducting similar studies to understand how exactly this virus is attacking the humans. Researchers also started studying the infection pattern of this virus in different countries and came out with the finding that there may be a unique mutation in the viral strain infecting the Indian population. And may be that is the reason why few countries are suffering large numbers of fatalities as compared to India.
Researchers from Taiwan and Australia have apparently found a coronavirus strain isolated in India carrying mutations in the spike protein’s receptor-binding domain (RBD) of the virus. A computer simulation shows that the RBD mutation that was not found in any other variants across the world, could remove a hydrogen bond from the spike protein. In the absence of this bond, the virus is less likely to bind to ACE2 that is found in the lungs and other organs.
このストーリーは、Bio Spectrum の May 2020 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
Can India's CDMOS Lead the Next Biopharma Wave?
India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).
8 mins
March 2026
Bio Spectrum
Telangana turns catalyst for innovation
Telangana is at a pivotal moment in its journey as a global life sciences hub.
6 mins
March 2026
Bio Spectrum
Is AI the New Weapon in the Fight to End TB?
A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).
2 mins
March 2026
Bio Spectrum
ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India
US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.
1 min
March 2026
Bio Spectrum
Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy
Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.
5 mins
March 2026
Bio Spectrum
"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"
Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.
5 mins
March 2026
Bio Spectrum
Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer
Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.
1 min
March 2026
Bio Spectrum
Haleon ropes in Kedar Lele as President for India Subcontinent
Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.
1 min
March 2026
Bio Spectrum
Centre revises Startup Recognition Framework to strengthen Startup India Action Plan
The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.
1 min
March 2026
Bio Spectrum
"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"
In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.
5 mins
March 2026
Translate
Change font size

